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The “estrogen paradox” in pulmonary arterial hypertension (PAH) refers to observations that while there is a higher incidence of
idiopathic PAH in women, rodent models of PAH show male dominance and estrogens are protective. To explain these diﬀerences,
we previously proposed the neuroendocrine-STAT5-BCL6 hypothesis anchored in the sex-biased and species-speciﬁc patterns of
growth hormone (GH) secretion by the pituitary, the targeting of the hypothalamus by estrogens to feminize GH secretion
patterns, and the role of the transcription factors STAT5a/b and BCL6 as downstream mediators of this patterned GH-driven
sex bias. As a test of this hypothesis, we previously reported that vascular smooth muscle cell- (SMC-) speciﬁc deletion of the
STAT5a/b locus abrogated the male-dominant sex bias in the chronic hypoxia model of PAH in mice. In the present study, we
conﬁrmed reduced BCL6 expression in pulmonary arterial (PA) segments in both male and female SMC:STAT5a/b−/− mice. In
order to test the proposed contribution of BCL6 to sex bias in PAH, we developed mice with SMC-speciﬁc deletion of BCL6+/−
by crossing SM22α-Cre mice with BCL6-ﬂoxed mice and investigated sex bias in these mutant mice in the chronic hypoxia
model of PAH. We observed that the male-bias observed in wild-type- (wt-) SM22α-Cre-positive mice was abrogated in the
SMC:BCL6+/− knockouts—both males and females showed equivalent enhancement of indices of PAH. The new data
conﬁrm BCL6 as a contributor to the sex-bias phenotype observed in hypoxic PAH in mice and support the neuroendocrineSTAT5-BCL6 hypothesis of sex bias in this experimental model of vascular disease.

1. Introduction
Idiopathic pulmonary arterial hypertension (IPAH) is a
disease with high morbidity and mortality with limited
therapeutic options [1–5]. The histologic vascular lesions in
the lungs are characterized by segmental pulmonary arterial
remodeling and proliferation of the vascular smooth muscle
and endothelial cells to form plexiform and “onion-skin” obliterative lesions which occlude the vascular lumen and cause
increased mean pulmonary artery pressure (>25 mm Hg)
and right ventricular hypertrophy [1–4]. Diverse inherited
autosomal-dominant mutations in the BMPR2 gene underlie
a signiﬁcant subset of IPAH cases, but with low penetrance

[1–4, 6–8]. There is a distinct sexual dimorphism in IPAH
in that this disease aﬀects postpubertal women (median age
at diagnosis: in the third decade) with 2–4-fold greater incidence than men (median age at diagnosis: in the fourth
decade) [1–11]. However, disease progression is more rapid
in men than in women [9]. The mechanisms that determine
this sexual dimorphism in humans are incompletely understood. Puzzlingly, several studies have pointed to a direct
protective eﬀect of estrogens on development of an equivalent
pulmonary arterial hypertension (PAH) disease process in
experimental animals (such as in mice and rats exposed to
chronic hypoxia or in rats exposed to monocrotaline pyrrole)
([9–21], and citations therein). Thus, in these experimental
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Figure 1: Schematic of the pathway involving the contributions of neuroendocrine-STAT5-BCL6 mechanisms of sex bias in PAH. Patterns of
circulating GH in males typically consist of a low baseline level with few (2–4) but high peak levels (a pattern customarily referred to as
“pulsatile”) [22–29]. Females have a higher baseline level of GH with small frequent peaks (≥7 per day) (a pattern referred to as “more
continuous”) [22–29]. E2, estradiol-17β; M, male; F, female; downward short arrows indicate reduction; upward short arrow indicates increase.

models in mice and rats it is the males that preferentially
develop more pronounced disease, while exogenously administered estrogens have proven to be protective.
In attempting to understand the mechanistic basis of this
species-dependent sex-bias paradox (higher incidence of
IPAH in women, but greater susceptibility to PAH in male
mice and rats, with exogenous estrogens having a protective
eﬀect) [9–18], we discovered that smooth muscle cells
(SMCs) in obliterative IPAH lesions in humans had a marked
reduction in levels of the sex-responsive transcription factors
STAT5a and STAT5b (collectively either “STAT5a/b” or
“STAT5”), their activated Tyr-phosphorylated entities
(PY-STAT5), and a downstream sex-responsive target of
STAT5—the “broad-spectrum” transcriptional repressor
B-cell lymphoma 6 protein (BCL6) (Figure 1) [19–21].
This discovery focused our attention on the possibility that
the resolution of the species-speciﬁc sex-bias paradox in
PAH between human females (greater susceptibility to
PAH than males) and rodent females (lesser susceptibility
to PAH than males) might reside in the well-known diﬀerences in the patterns of sex-biased secretion of growth
hormone (GH)—a well-characterized upstream activator of
STAT5a/b [19–21]. Women have a high baseline level of
GH with small frequent peaks (a pattern referred to as “more
continuous”), while men have a low baseline with few but
high level peaks of GH (a pattern referred to as “pulsatile”)
([20–29], and citations therein) (Figure 1). Thus, circulating
GH levels in men comprise 2–4 peaks per day with very
low interpulse levels, while in women there is a higher frequency of pulses (>7 peaks/day) with signiﬁcantly elevated
interpulse levels (Figure 1) ([22–25]; reviewed in [20, 21]).
Even when assayed at a single time-point in humans (in the
morning after fasting), the median value of serum GH levels
was 80–120-fold higher in young adult women than in young
adult men [25]. This is a higher sexual dimorphism ratio than
that for estradiol-17β (E2) (ratio: 2.2-fold female bias) or testosterone (ratio: 14-fold male bias) observed in the same sera
[25]. Mice and rats also show similar quantitative diﬀerences
in the respective male versus female patterns of circulating
GH ([26–29], reviewed in [21]) (Figure 1). Male rodents
show discrete GH pulses approximately every 3–5 hr with little or no circulating GH detectable during the interpulse
interval, while in female rats, the pulses are more frequent,
the pulse heights are lower, and the interpulse levels are

relatively low but nonzero [26–29]. Overall, when compared
to GH levels at peak pulse height, female humans have a
relatively high interpulse level, while female rodents have a
low interpulse level ([22–29]; reviewed in [20, 21]). We have
pointed to this diﬀerence in relative interpulse levels as a key
diﬀerence between women and female rodents that might
underlie the estrogen paradox [19–21]. It is noteworthy that
the pulsatility in GH levels is largely unconnected to the
day-night circadian rhythms or the pulsatility of the cardiac
cycle [20–29].
There is extensive neuroendocrinology literature showing that these patterns are derived from the patterned secretion of GH by the anterior pituitary in response to
hypothalamic input via neuronal GHRH secretion which is
in turn aﬀected by estrogens (e.g., estradiol-17β (E2)) at the
level of the arcuate nucleus (and other sites) in the ventromedial hypothalamus [30–42]. In terms of downstream mechanisms, there is also extensive literature mechanistically
linking these GH pulsatility patterns to patterned activation
of STAT5a/b (frequency and level of activation by Tyr phosphorylation) with resulting patterned activation of the transcriptional repressor BCL6 and hundreds of downstream
genes (Figure 1) [43–51]. Remarkably, it has been established
beginning in the late 1970s that the feminizing eﬀect of exogenously administered estrogens on liver gene expression
obligatorily required the pituitary in that hypophysectomy
blocked this sex-bias eﬀect of estrogens (Figure 1) [30–42].
Thus, although there is considerable research on the interactions between the estrogens, the estrogen receptors, and
STAT5 and other transcription factors at the level of distal
target tissues [47], there is also clear evidence that a major
mechanism of the sex-bias eﬀects of exogenously administered estrogens begins with the interaction of sex hormones
with the hypothalamus and changes in the subsequent cascade of patterned activation of the GH-STAT5 axis in distal
tissues (Figure 1) [30–51]. Thus, especially in light of the
“estrogen paradox” in PAH [6, 9], we proposed the
neuroendocrine-STAT5 hypothesis of sex bias in this disease
to account for the diﬀerence between humans and rodents
(Figure 1) [19–21].
Experimentally, after observing that SMCs in obstructive
pulmonary arterial lesions in IPAH in both female and male
patients showed reduced STAT5a/b and reduced PY-STAT5
[19], we tested the STAT5 hypothesis of sex bias in PAH in
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the chronic hypoxia model in mice. In this model, wild-type
(wt) mice show a male-dominant phenotype. We developed
tissue-speciﬁc knockout mice with heterozygous or homozygous deletion of STAT5a/b in vascular smooth muscle cells
(SMCs) and investigated the inﬂuence of these deletions on
the male dominance in this model of PAH [19]. We observed
that SMC-speciﬁc heterozygous or homozygous deletion of
STAT5a/b abrogated the male-dominant sex bias in that both
female and male mice developed PAH (increased right ventricular systolic pressure (RVSP), hypertrophy of pulmonary
arterial vessel wall, and right ventricular hypertrophy) to a
similar extent [19–21].
We then focused on experimentally testing a downstream
element in the GH-STAT5 hypothesis (Figure 1). It is well
established that the transcriptional repressor BCL6 is one of
the major transcription factors downstream of STAT5 in
the sex-biased regulation of expression of hundreds of liver
genes [50, 51]. We have previously reported that BCL6 was
also reduced in SMCs in obliterative pulmonary arterial
lesions in both women and men with IPAH concomitant
with the reduction in STAT5a/b and PY-STAT5 levels [21].
It is also already known that whole-body homozygous deletion of BCL6−/− in the mouse led to extensive pulmonary
edema and pulmonary parenchymal and vascular inﬂammation [52]. Thus, from the point of view of downstream
mechanisms in the STAT5 hypothesis, we investigated (a)
whether SMC-speciﬁc deletion of STAT5a/b in the mouse
had an eﬀect on expression of BCL6 in SMCs in pulmonary
arterial tunica media and (b) whether SMC-speciﬁc deletion
of BCL6 in the mouse had an eﬀect on chronic hypoxiainduced PAH and its male-dominant sex-bias phenotype
(Figure 1). The new data reported here represent a successful
test of the BCL6 element in the GH-STAT5-BCL6 hypothesis
of sex bias in PAH [19–21].

3
segments in the Cre-positive heterozygous STAT5a/b wt/ﬂ
(designated “+/−”) or homozygous ﬂ/ﬂ (designated “−/−”)
mice was veriﬁed in immunoﬂuorescence and immunohistochemistry assays for STAT5 [19]. Smooth muscle α-actin(SMA-) positive aortic smooth muscle cells (SMCs) derived
from the homozygous knockouts showed a marked loss of
STAT5a/b by Western blotting [19]. Lung tissues from Wt
and SMC:STAT5a/b−/− mice used in the immunoﬂuorescence analyses for BCL6 were from experiments previously
reported in Figure 4 in [19].
Mouse lines (in C57BL/6 background) with SMC-speciﬁc
heterozygous and homozygous deletions of BCL6 were generated in the same manner described above by cross-mating
the BCL6ﬂ/ﬂ (B6.129S (FVB)-Bcl6tm1.1Dent/J; stock number:
023727 Bcl6ﬂ) and SM22α-Cre+/+ mice (stock number:
004746) purchased from The Jackson Laboratories, Bar
Harbor, ME, and conﬁrmed by PCR analyses of tail DNA
using appropriate primers designated by the supplier. All
mice in the BCL6 studies designated “Wt” were Cre-positive
littermates not carrying any BCL6-ﬂoxed alleles. Reduced
expression of BCL6 in the tunica media and SMCs of pulmonary artery segments of the mutant mice was conﬁrmed by
immunoﬂuorescence analyses (Figure 2). These mutant mice,
including the SMC-speciﬁc STAT5a/b−/− and SMC-speciﬁc
BCL6+/− and −/− knockouts have no fertility or growth
issues. In the present study, we used the more abundantly
available male and female heterozygous SMC-speciﬁc BCL6
+/− for the chronic hypoxia treatment.

2. Materials and Methods

2.2. Exposure to Hypoxia. Groups of Wt, or mutant male and
female mice at approximately 8 weeks of age were used in the
respective chronic hypoxia experiments (n = 4 – 7 mice per
group per variable; average group size n = 5 mice) [19]. Mice
were exposed to hypobaric hypoxia (0.5 atmospheres in
room air equivalent to 10% v/v oxygen) for approximately 4
weeks; normoxia controls were left in ordinary room air [19].

2.1. Derivation of Mice with Smooth Muscle Cell- (SMC-)
Speciﬁc Heterozygous and Homozygous Deletions of
STAT5a/b or BCL6. Mouse breeding, care, and use of
animals for these studies was approved by the Institutional
Animal Care and Use Committee (IACUC) of the New York
Medical College. A mouse line with SMC-speciﬁc homozygous deletion of the STAT5a/b locus had been previously
produced by mating STAT5a/bﬂ/ﬂ mice carrying loxP inserts
bracketing the entire STAT5a/b locus in C57BL/6:129J mice
provided by Dr. Lothar Hennighausen (National Institutes
of Health, Bethesda, MD) with SM22-Cre+/+ mice (expressing Cre recombinase under the control of the mouse transgelin (smooth muscle protein 22α) promoter) purchased from
The Jackson Laboratories, Bar Harbor, ME (stock number:
004746 Tg (Tagln-cre)1Her/J in C57BL/6:129SJL background) [19]. PCR analyses of the tail DNA using appropriate primers were used to conﬁrm the genotype of the
Cre-positive mice with respect to the presence of STAT5a/b
wt or ﬂ or Cre alleles [19]. All mice in the present studies designated “Wt” were Cre-positive littermates not carrying any
STAT5a/b-ﬂoxed alleles [19]. The selective reduction in
STAT5 expression in the tunica media of pulmonary arterial

2.3. Assessment of PAH and Lung Vascular Remodeling after
Chronic Hypoxia. This was carried out as previously
described in [19]. Brieﬂy, mice were anaesthetized using the
ketamine/xylazine cocktail (100 mg/kg ketamine, 10 mg/kg
xylazine, intraperitoneally). A Millar catheter was used for
the in vivo measurement of right ventricular systolic pressure
(RVSP) via external jugular vein catheterization (PVR-1030;
Millar Instruments Inc., Houston, TX). The animals were
then euthanized and the heart, aorta, and left lung removed
and formalin ﬁxed (the right lung was snap-frozen in
liquid N2). The heart was dissected to obtain the ratio of
right ventricle weight to that of the left ventricle plus septum
(RV/LV + S) as a measure of right ventricular hypertrophy
(RVH). The left lung was used for paraﬃn block embedding
and histology (hematoxylin & eosin, Van Gieson’s elastin
and Masson’s Trichrome stains, and immunoﬂuorescence
for smooth muscle actin (SMA)). The extent of vascular
remodeling in pulmonary arteries with an outer diameter < 80 μm was quantitated in terms of medial wall thickness
expressed as 2x wall thickness in % of average vessel outer
diameter measured in two axes perpendicular to each other
[19]. Muscularization of pulmonary vessels in lung sections
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Figure 2: Reduced BCL6 expression in the tunica media/SMCs in sections of the main PA arteries in mice with SMC-speciﬁc heterozygous or
homozygous deletion of the BCL6 locus. Sections of the main PA arteries from Wt and respective mutant mice were evaluated for BCL6
expression by quantitative immunoﬂuorescence. (a) Autoﬂuorescence (in green) of the elastic laminae was used to identify the tunica
media. (c) SMCs in the tunica media were immunostained for smooth muscle α actin (SMA). Arrows in the Wt sections draw attention to
areas of normal BCL6 immunoﬂuorescence and those in the mutant sections to areas with reduced BCL6 expression. (b, d) Summary of
BCL6 immunoﬂuorescence intensity in multiple areas of sections such as in (a) and (c) in the Wt and respective mutant mice. ∗ P < 0 05
by Student’s t-test.

was evaluated as indicated in Section 2.4. All histological
quantitation was carried out in a blinded fashion.
2.4. Immunoﬂuorescence Analyses of Lung Sections. Serial
sections (5 μm) of formalin-ﬁxed, paraﬃn-embedded lung
tissue were evaluated for BCL6 and smooth muscle α-actin
(SMA) immunoﬂuorescence as described earlier [19] using
rabbit pAb for BCL6 or mouse mAb for SMA, and respective
donkey AlexaFluor 594-tagged pAb (in red) as the secondary
antibody. Imaging was carried out using a Zeiss AxioImager
M2 motorized microscopy system equipped with a highresolution RGB HRc AxioCam camera and AxioVision
4.8.1 software in a 1388 × 1040 pixel high-speed color capture
mode. All data within each experiment were collected at
identical imaging settings. Fluorescence intensity was quantitated using the NIH Image J software [19]. Muscularization

of pulmonary vessels < 80 μm in diameter was evaluated by
immunoﬂuorescence of SMA in lung sections and expressed
as the mean number of SMA-positive vessels per 10x
objective ﬁeld.
2.5. Antibodies. Rabbit pAb to BCL6 (N-3) (Cat. number:
sc-858) was purchased from Santa Cruz Inc., Santa Cruz,
CA. Mouse mAb to SMA (Cat. number: A5228) was from
Sigma-Aldrich Inc., St. Louis, MO. Alexa-Flour-tagged
donkey secondary antibodies were from Life Technologies,
Grand Island, NY.
2.6. Statistical Evaluations. These were performed using the
two-tailed Student t-test (as in Figure 2) and single-factor
ANOVA methods (NCSS version 8, 2012). Multiple group
comparisons were carried out using ANOVA (TukeyKramer, Newman-Keuls, and Tukey-Kramer tests).
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Figure 3: Reduced BCL6 expression in pulmonary arterial (PA) segments in SMC:STAT5a/b−/− male and female mice in normoxia and
hypoxia. (a) Representative immunoﬂuorescence images for expression of BCL6 in PA segments in lungs of Wt and SMC:STAT5a/b−/−
male and female mice (arrows) kept for 4 weeks in normoxia or hypoxia. The lung sections used for this experiment derive from the
mouse experiment reported in Figure 4 in [19]. Scale bar = 20 μm. (b) Quantitation of BCL6 expression in PA segments as illustrated in
(a) expressed as a ratio of ﬂuorescence in PA segments compared to that in the adjacent bronchial epithelium in the same section. n = the
number of arterial segments quantitated per group; ∗ P < 0 05 by ANOVA.

3. Results
3.1. SMC-Speciﬁc STAT5a−/− Deletion Leads to Reduced
BCL6 Expression in Pulmonary Arterial Tunica Media. We
used quantitative immunoﬂuorescence methods to investigate whether BCL6 might be downstream of STAT5 in
SMCs in the pulmonary arterial vasculature. Groups of male
and female Wt and STAT5−/− mice were exposed to hypoxia (10% hypobaric oxygen) for 4 weeks or kept under normoxic conditions, and the development of PAH was ﬁrst
evaluated as previously reported (RVSP, ratio of RV/LV + S
weights, increased muscularization of vessels, and increased
arterial wall thickness) [19]. From the data previously
reported, we observed in this experiment that STAT5−/−
deletion abrogated the male-dominant phenotype of PAH

in this model—the knockout female and male mice developed equivalently high levels of PAH [19]. There was little
change in heart rate or systemic blood pressure in these mice
[19]. Subsequently, representative formalin-ﬁxed paraﬃnblock sections of lungs were quantitatively evaluated for
expression of BCL6 in the pulmonary arterial (PA) walls as
a ratio to that in bronchial epithelium in diﬀerent groups
(Figure 3). The immunoﬂuorescence data in Figure 3(a)
(arrows) and the quantitation summarized in Figure 3(b)
show a reduction in BCL6 immunoﬂuorescence in PA
segments in male and female STAT5−/− mice under both
normoxic and hypoxic conditions. These data were consistent
with the positioning of BCL6 downstream of STAT5 in
mouse pulmonary arterial SMCs in a manner similar to
its downstream position to STAT5 in the mouse liver
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Figure 4: Abrogation of the male sex bias in chronic hypoxia-induced PAH in SMC:BCL6+/− mice: right ventricular systolic pressures
(RVSP). Groups of male and female Wt and SMC:BCL6+/− knockout mice (n = 4–7 mice per group as indicated) were subjected to
hypobaric hypoxia (10% v/v oxygen) or kept in room air for 4 weeks. At the end of the experiment, Millar catheterization was used to
measure the RVSP (Figure 4 and [19]), the PA wall thickness (see Figure 5), muscularization of PA vessels in lung sections (Figure 6(a)),
and right ventricular hypertrophy (the ratio of RV/LV + S wet weights) (Figure 6(b)). (a) Mean RVSP is shown in each group (mean ± SE).
(b) The RVSP for each individual mouse is shown.∗ P < 0 05 by ANOVA; NS, not signiﬁcant.

(Figure 1) [49–51]. These data are consistent with the inference that STAT5a/b are positive transcription factors for
expression of BCL6 in pulmonary arterial tissue (Figure 1),
an inference previously validated extensively in the liver and
isolated hepatocytes by Waxman and colleagues [47–51].
3.2. Development of SMC-Speciﬁc BCL6+/− and BCL6−/−
Knockout Mice. We generated lines of C57Bl6 mice with
heterozygous or homozygous deletions of the BCL6 locus in
vascular SMCs in crosses between BCL6ﬂ/ﬂ and transgelin
(SM22α)-Cre+/+ parents using methods previously described
for the generation of SMC-speciﬁc STAT5+/− and −/− mice
[19]. In addition to molecular characterization (using PCR
methods summarized in [19]; data not shown), quantitative
immunoﬂuorescence methods were used to verify the
reduced expression of BCL6 in the pulmonary arterial tunica
media and SMCs in mice with SMC:BCL6+/− deletion
(Figures 2(a) and 2(b)) and SMC:BCL6−/− deletion
(Figures 2(c) and 2(d)). SMC-speciﬁc heterozygous and
homozygous deletion of BCL6 reduced the levels of expression of BCL6 in the tunica media/SMCs in PA segments of
the respective knockout mice but not in the endothelium
(Figures 2(a) and 2(c)).
3.3. Abrogation of the Male-Dominant Sex Bias in Hypoxic
PAH in BCL6+/− Mice. We were able to generate suﬃcient

SMC:BCL6+/− mice and Cre-positive “wt” littermates of
both sexes to provide groups of 4–7 mice for evaluation
indices of PAH per variable as indicated in Figure 4. (Only
a limited number of SMC:BCL6−/− mice were generated in
this project; these provided conﬁrmatory preliminary data;
see below.) Male and female Wt and SMC:BCL6+/− mice
(n = 4–7 per group) were exposed to 10% hypobaric oxygen
or normoxia for 4 weeks and evaluated for development of
PAH. The data in Figure 4(a) show the mean RVSP in these
groups in normoxia and in response to chronic hypoxia.
There is a clear male-dominant phenotype in the increase
in mean RVSP in Wt mice in response to hypoxia. In contrast, this sex bias was absent in BCL6+/− mice; both males
and females showed increased RVSP in response to hypoxia.
Figure 4(b) shows the RVSP data for individual mice. The
data show that even under normoxia, one male and three
female BCL6+/− mice had RVSP levels > 25 mm Hg. Moreover, all male and female BCL6+/− hypoxic mice had markedly elevated RVSPs (Figure 4(b)). Overall, the data in
Figure 4 provide evidence showing that (a) even an heterozygous deletion of BCL6 in vascular SMCs led to an enhancement of the chronic hypoxia-induced increase in RVSP
irrespective of sex, and (b) that there was a detectable
increase in RVSP even in male and female knockout mice
under normoxic conditions (Figure 4(a)). In preliminary
studies, male and female homozygous SMC:BCL6−/− mice
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Figure 5: Abrogation of the male-sex bias in chronic hypoxia-induced PAH in SMC:BCL6+/− mice: hypertrophy of PA arterial wall
thickness. Lungs derived from the experiment in Figure 4 were processed for histological sections and stained for elastin using Van
Giesson’s reagent. Wall thickness of PA segments with a diameter < 80 μm was quantitated in terms of the ratio of 2x wall thickness/outer
diameter as reported earlier [14]. (a) Representative histologic sections are illustrated. (b) The numerical data (mean ± SE) are
summarized. Scale bar = 20 μm. ∗ P < 0 05 by ANOVA; NS, not signiﬁcant.

also showed an equivalent enhancement of RVSP after
chronic hypoxia (data not shown).
Figures 5(a) and 5(b) summarize pulmonary arterial wall
thickness data from the experiment in Figure 4. Again, the
male-dominant sex bias in response to chronic hypoxia in
terms of increased wall thickness in Wt mice was abrogated
in BCL6+/− mice (Figures 5(a) and 5(b)). Moreover, there
appeared to be an increase in wall thickness in both male
and female knockout mice even under normoxic conditions
(Figure 5(b)). Figure 6(a) summarizes data pertaining to
increased muscularization of pulmonary vessels in lung
sections from hypoxic mice, while Figure 6(b) summarizes

development of right ventricular hypertrophy measured in
terms of the Fulton index (ratio of RV/LV + S weights). As
expected, a male-dominant phenotype was observed in Wt
hypoxic mice, but there was little sex bias in hypoxic
SMC:BCL6+/− mice in terms of these indices of PAH
(Figures 6(a) and 6(b)).
Taken together the data in Figures 4–6 provide evidence
for a contribution of BCL6 in the sex-bias phenotype of
PAH observed in chronically hypoxic mice. Even heterozygous deletion of BCL6 in vascular SMCs rendered female
mice equally susceptible to the development of hypoxic
PAH as male mice. This observation was similar to our
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Figure 6: Abrogation of the male sex bias in chronic hypoxia-induced PAH in SMC:BCL6+/− mice: muscularization of pulmonary vessels in
lung sections and right ventricular hypertrophy (Fulton’s index). (a) Lung sections from mice shown in Figure 4 were immunostained for
SMA and the average number of muscularized vessels per 10x ﬁeld were enumerated for each (mean ± SE). (b) Hearts derived from the
experiment in Figure 4 were ﬁxed in 4% formalin, rinsed in PBS and dissected into the right ventricle (RV) and the left ventricle plus
septum (LV + S) portions. The ratio of the wet weights of RV/LV + S (mean ± SE) illustrates the extent of right ventricular hypertrophy
irrespective of the total weight of the individual heart. ∗ P < 0 05 by ANOVA; NS, not signiﬁcant.

previous ﬁnding that heterozygous SMC-speciﬁc deletion of
STAT5a/b was suﬃcient to abrogate the male-speciﬁc sex
bias in the hypoxic mouse model [19].

4. Discussion
This study represents a speciﬁc test of the downstream BCL6
element in the GH-STAT5-BCL6 hypothesis of sex bias in
PAH (Figure 1) [19–21]. In a previous study, we provided
experimental support for this hypothesis by showing that
vascular SMC-speciﬁc deletion of the STAT5a/b locus in
mice abrogated the male-dominant sex bias observed in the
chronic hypoxic PAH model [19]. In the present study, we
have tested the next downstream element—BCL6—in this
hypothesis (Figure 1). Consistent with its placement downstream of STAT5 [49–51], we observed reduced BCL6 levels
in the tunica media/SMCs in pulmonary arterial segments
in male and female mice with homozygous SMC-speciﬁc
deletion of STAT5a/b (Figure 3). We then investigated
whether SMC-speciﬁc deletion of BCL6 (+/−) aﬀected the
observed sex bias in the chronic hypoxia model. We
observed the abrogation of the male-dominance in the development of PAH in the knockout mice. Both male and female
SMC:BCL6+/− knockout mice responded equally to chronic
hypoxia in terms of PAH development (Figures 4–6). Thus,
these data place BCL6 in the STAT5-anchored sex-bias pathway in this experimental model and represent a successful
critical test of the GH-STAT5-BCL6 hypothesis of sex bias
in a vascular disease.
The novelty of the present study resides in the realization that insights accumulated over the last 30–40 years in
a sister ﬁeld (sex-biased expression of liver genes) and the

neuroendocrine mechanisms by which exogenously administered estrogens inﬂuences these (Figure 1) [30–51] is largely
missing from the vascular biology ﬁeld, and especially the
pulmonary hypertension ﬁeld [1–18]. The critical insight
from the liver ﬁeld from the 1970s, was that the eﬀects of
exogenously administered estrogens on feminization of sexbiased gene expression in the liver in rodent models were
absolutely dependent on the pituitary—hypophysectomy
blocked the feminization (Figure 1) [30–42]. The target of
injected estrogens included the arcuate nucleus, and additional nuclei, in the hypothalamus (Figure 1) [30–42]. In
terms of vascular biology, that hypophysectomy in the male
rat markedly impaired arterial remodeling after aortic balloon injury in terms of reduced vascular SMC proliferation
and myointima formation, was reported in 1978 [53], and
conﬁrmed [54], but this research was not pursued further.
Moreover, that ghrelin, a GH secretagogue and vasodilator
(which antagonizes endothelin-1), inhibited hypoxia- or
monocrotaline-induced PA remodeling in male rats is now
known [55–57], yet neuroendocrine mechanisms have
received little attention in the sex bias observed in vascular
disease. Thus far, most research on sex bias in the vascular
ﬁeld has focused on the direct eﬀects of sex hormones on
vascular tissues [6, 7, 9–18].
As elucidated in detail by Waxman et al. and other investigators in the last two-three decades, this neuroendocrine
mechanism of sex bias, operating through an axis consisting
of the arcuate nucleus, growth hormone releasing hormone
(GHRH), growth hormone (GH), and signal transducer and
activator of transcription 5 (STAT5), accounts for sexbiased expression of ~500–1000 genes in the liver, and also
of body growth and body weight (Figure 1) [43–51].
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Downstream of STAT5 is a major cascade of sex-speciﬁc
regulated gene expression of 500–1000 genes (including
other transcription repressors such as BCL6; transcription
activators such as Cux2, HNF4α, HNF6, and P450 CYP
enzyme species; cell-cycle regulators; cytokines; growth factors; and immune mediators) [43–51]. As a foundational
experiment in the liver ﬁeld, Waxman et al. [43–46] observed
that the conditional liver-speciﬁc deletion of the STAT5a/b
locus in the mouse using the albumin-Cre and loxP
approach led to the abrogation of sex-biased gene expression
in the liver.
We studied STAT5a/b in vascular cells in terms of its
contribution to the sex-bias phenotype in PAH induced in
mice following chronic hypoxia [19–21]. We generated
mice with heterozygous or homozygous conditional deletions of the STAT5a/b locus in vascular smooth muscle cells
(SMCs). Although, Wt males subjected to hypoxic stress
showed signiﬁcant pulmonary arterial and cardiac remodeling, with Wt females showing minimal changes (a maledominant phenotype), the SMC-speciﬁc STAT5 −/− mice
hypoxic females showed the severest manifestations of PA
remodeling (a female-dominant phenotype) [19]. The
reversal of sex bias in this model of PAH did not require
the complete loss of STAT5a/b genes. Even heterozygous
conditional STAT5a/b+/− mice (thus, with a 50% loss of
STAT5a/b) showed a loss of the male-dominant PAH phenotype [19]. The observation in the present study that these
SMC:STAT5a/b−/− mice also showed reduced expression of
BCL6 in the tunica media/SMCs in pulmonary arterial segments in both normoxic and hypoxic mice irrespective of
sex (Figure 3) was consistent with the known role of STAT5
as a transcription factor activating BCL6 gene expression
(Figure 1) [47–51]. In as much as it is known that BCL6
is a broad-spectrum transcriptional repressor [49–52], the
reduced expression of BCL6 in SMC:STAT5a/b−/− mice
prompted us to test the involvement of BCL6 per se in
the sex bias observed in this model of PAH by genetically
deleting BCL6 in SMCs in mice. Since it has already been
shown that mice with whole-body knockout of the transcriptional repressor BCL6 showed increased production of
proinﬂammatory cytokines (IL-6, IFN-gamma, and IL-4),
developed generalized vasculitis including pulmonary vasculitis, grew poorly, and lived only 6–8 weeks [52], in the
present study we speciﬁcally investigated the eﬀects of
tissue-speciﬁc BCL6 deletion only in vascular SMCs.
We discovered that SMC-speciﬁc deletion of BCL6 led
to an abrogation of the male-dominant sex bias seen in
hypoxic Wt mice. The data provide evidence for the
involvement of the BCL6 axis in the sex bias observed in
the chronic hypoxia-induced model of PAH in mice. This
represents a successful test of the neuroendocrine-STAT5
hypothesis of sex bias in hypoxic PAH in mice in terms
of the involvement of a predicted downstream player—the
involvement of BCL6.
In preliminary experiments, we have initiated tests of the
involvement of the predicted upstream participant—the
pituitary—in sex bias in hypoxic PAH in mice (Figure 1).
Preliminary data suggest that hypophysectomy also abrogates the sex bias observed in Wt mice (data not shown).
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We have previously reported that a marked decrease in
STAT5a/b and BCL6 was observed in SMCs in obliterative
lesions in human IPAH—in women and men [19, 21]. These
observations suggested a role of aberrations in the STAT5BCL6 axis in the pathogenesis of the human disease. It is long
established that 30–50% of patients with acromegaly develop
systemic hypertension [58–60]. Although respiratory complications in acromegaly are known to include sleep-breathing
disorders and “respiratory insuﬃciency” [60], there is little
information about the pulmonary arterial circulation per se
in such patients. Whether patients with IPAH have altered
GH secretion kinetics could be evaluated using patterns of
exercise-induced GH secretion [61–63].

5. Conclusions
The present study represents a successful test of one
downstream element—BCL6—in the neuroendocrine-GHSTAT5-BCL6 sex-bias hypothesis in an experimental model
of PAH. The insights obtained are likely to apply to sex bias
in other vascular disease models and the human disease
[20, 21]. While the present study has focused on the neuroendocrine pathway that indirectly mediates the feminizing
eﬀect of estrogens, we realize that there are extensive studies
that highlight the direct eﬀects of estrogens in vascular tissues
[6, 7, 9–18]. From our perspective, the development of sexual
dimorphism in vascular disease likely includes both upstream
indirect eﬀects initiated by sex hormones at the hypothalamus
and mediated through the GH-STAT5-BCL6 pathway
[19–21] as well as direct eﬀects of sex hormones on vascular
cells [6, 7, 9–18].

Data Availability
The data used to support the ﬁndings of this study are
included within the article.

Conflicts of Interest
The authors declare no conﬂicts of interest.

Authors’ Contributions
Yang-Ming Yang and Pravin B. Sehgal designed the experiments, carried out all the work, and wrote the manuscript.

Funding
This study was supported, in part, by Research Grant
HL-114509 from the National Heart, Lung, and Blood
Institute, the National Institutes of Health, and by Bridge
Funding from the New York Medical College.

References
[1] R. M. Tuder, J. C. Marecki, A. Richter, I. Fijalkowska, and
S. Flores, “Pathology of pulmonary hypertension,” Clinics in
Chest Medicine, vol. 28, no. 1, pp. 23–42, 2007.

10
[2] M. Rabinovitch, “Molecular pathogenesis of pulmonary
arterial hypertension,” The Journal of Clinical Investigation,
vol. 118, no. 7, pp. 2372–2379, 2008.
[3] N. W. Morrell, “Role of bone morphogenetic protein receptors
in the development of pulmonary arterial hypertension,”
Advances in Experimental Medicine and Biology, vol. 661,
pp. 251–264, 2010.
[4] E. Stacher, B. B. Graham, J. M. Hunt et al., “Modern age
pathology of pulmonary arterial hypertension,” American
Journal of Respiratory and Critical Care Medicine, vol. 186,
no. 3, pp. 261–272, 2012.
[5] M. K. Hensley, A. Levine, M. T. Gladwin, and Y. C. Lai,
“Emerging therapeutics in pulmonary hypertension,” American
Journal of Physiology-Lung Cellular and Molecular Physiology,
vol. 314, no. 5, pp. L769–L781, 2018.
[6] E. D. Austin, J. D. Cogan, J. D. West et al., “Alterations in
oestrogen metabolism: implications for higher penetrance of
familial pulmonary arterial hypertension in females,” European Respiratory Journal, vol. 34, no. 5, pp. 1093–1099, 2009.
[7] E. D. Austin, R. Hamid, A. R. Hemnes et al., “BMPR2 expression is suppressed by signaling through the estrogen receptor,”
Biology of Sex Diﬀerences, vol. 3, no. 1, p. 6, 2012.
[8] J. P. Fessel, J. E. Loyd, and E. D. Austin, “The genetics of
pulmonary arterial hypertension in the post-BMPR2 era,”
Pulmonary Circulation, vol. 1, no. 3, pp. 305–319, 2011.
[9] T. Lahm, R. M. Tuder, and I. Petrache, “Progress in solving the
sex hormone paradox in pulmonary hypertension,” American
Journal of Physiology-Lung Cellular and Molecular Physiology,
vol. 307, no. 1, pp. L7–L26, 2014.
[10] K. M. Mair, A. K. Z. Johansen, A. F. Wright, E. Wallace, and
M. R. MacLean, “Pulmonary arterial hypertension: basis of
sex diﬀerences in incidence and treatment response,” British
Journal of Pharmacology, vol. 171, no. 3, pp. 567–579, 2014.
[11] S. Umar, M. Rabinovitch, and M. Eghbali, “Estrogen paradox
in pulmonary hypertension—current controversies and future
perspectives,” American Journal of Respiratory and Critical
Care Medicine, vol. 186, no. 2, pp. 125–131, 2012.
[12] A. Liu, D. Schreier, L. Tian et al., “Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension,” American
Journal of Physiology-Heart and Circulatory Physiology,
vol. 307, no. 3, pp. H273–H283, 2014.
[13] A. L. Frump, K. N. Goss, A. Vayl et al., “Estradiol improves
right ventricular function in rats with severe angioproliferative
pulmonary hypertension: eﬀects of endogenous and exogenous sex hormones,” American Journal of Physiology-Lung
Cellular and Molecular Physiology, vol. 308, no. 9, pp. L873–
L890, 2015.
[14] K. White, Y. Dempsie, M. Nilsen, A. F. Wright, L. Loughlin,
and M. R. MacLean, “The serotonin transporter, gender, and
17β oestradiol in the development of pulmonary arterial
hypertension,” Cardiovascular Research, vol. 90, no. 2,
pp. 373–382, 2011.
[15] Y. Dempsie, M. Nilsen, K. White et al., “Development of
pulmonary arterial hypertension in mice over-expressing
S100A4/Mts1 is speciﬁc to females,” Respiratory Research,
vol. 12, no. 1, p. 159, 2011.
[16] J. P. Fessel, X. Chen, A. Frump et al., “Interaction between
bone morphogenetic protein receptor type 2 and estrogenic
compounds in pulmonary arterial hypertension,” Pulmonary
Circulation, vol. 3, no. 3, pp. 564–577, 2013.

International Journal of Endocrinology
[17] K. M. Mair, X. D. Yang, L. Long et al., “Sex aﬀects bone morphogenetic protein type II receptor signaling in pulmonary
artery smooth muscle cells,” American Journal of Respiratory
and Critical Care Medicine, vol. 191, no. 6, pp. 693–703, 2015.
[18] A. F. Wright, M. A. Ewart, K. Mair et al., “Oestrogen receptor
alpha in pulmonary hypertension,” Cardiovascular Research,
vol. 106, no. 2, pp. 206–216, 2015.
[19] Y. M. Yang, H. Yuan, J. G. Edwards et al., “Deletion of
STAT5a/b in vascular smooth muscle abrogates the male bias
in hypoxic pulmonary hypertension in mice: implications in
the human disease,” Molecular Medicine, vol. 20, pp. 625–
638, 2015.
[20] P. B. Sehgal, Y. M. Yang, and E. J. Miller, “Hypothesis: neuroendocrine mechanisms (hypothalamus-growth hormone-STAT5
axis) contribute to sex bias in pulmonary hypertension,”
Molecular Medicine, vol. 21, no. 1, pp. 688–701, 2015.
[21] P. B. Sehgal, Y. M. Yang, H. Yuan, and E. J. Miller, “STAT5a/b
contribute to sex bias in vascular disease: a neuroendocrine
perspective,” JAK-STAT, vol. 4, no. 3, pp. 1–20, 2015.
[22] L. M. Winer, M. A. Shaw, and G. Baumann, “Basal plasma
growth hormone levels in man: new evidence for rhythmicity
of growth hormone secretion,” The Journal of Clinical Endocrinology & Metabolism, vol. 70, no. 6, pp. 1678–1686, 1990.
[23] G. van den Berg, J. D. Veldhuis, M. Frolich, and F. Roelfsema,
“An amplitude-speciﬁc divergence in the pulsatile mode of
growth hormone (GH) secretion underlies the gender diﬀerence in mean GH concentrations in men and premenopausal
women,” The Journal of Clinical Endocrinology & Metabolism,
vol. 81, no. 7, pp. 2460–2467, 1996.
[24] S. M. Pincus, E. F. Gevers, I. C. Robinson et al., “Females
secrete growth hormone with more process irregularity than
males in both humans and rats,” American Journal of
Physiology-Endocrinology and Metabolism, vol. 270, 1, Part 1,
pp. E107–E115, 1996.
[25] B. E. Engström, F. A. Karlsson, and L. Wide, “Marked gender
diﬀerences in ambulatory morning growth hormone values
in young adults,” Clinical Chemistry, vol. 44, 6, Part 1,
pp. 1289–1295, 1998.
[26] S. Edén, “Age- and sex-related diﬀerences in episodic growth
hormone secretion in the rat,” Endocrinology, vol. 105, no. 2,
pp. 555–560, 1979.
[27] J. N. MacLeod, N. A. Pampori, and B. H. Shapiro, “Sex diﬀerences in the ultradian pattern of plasma growth hormone concentrations in mice,” Journal of Endocrinology, vol. 131, no. 3,
pp. 395–399, 1991.
[28] J. C. Painson and G. S. Tannenbaum, “Sexual dimorphism of
somatostatin and growth hormone-releasing factor signaling
in the control of pulsatile growth hormone secretion in the
rat,” Endocrinology, vol. 128, no. 6, pp. 2858–2866, 1991.
[29] R. N. Dhir and B. H. Shapiro, “Interpulse growth hormone
secretion in the episodic plasma proﬁle causes the sex reversal
of cytochrome P450s in senescent male rats,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 100, no. 25, pp. 15224–15228, 2003.
[30] H. D. Colby, J. H. Gaskin, and J. I. Kitay, “Requirement of the
pituitary gland for gonadal hormone eﬀects on hepatic corticosteroid metabolism in rats and hamsters,” Endocrinology,
vol. 92, no. 3, pp. 769–774, 1973.
[31] R. E. Kramer, J. W. Greiner, R. C. Rumbaugh, T. D. Sweeney,
and H. D. Colby, “Requirement of the pituitary gland for
gonadal hormone eﬀects on hepatic drug metabolism in rats,”

International Journal of Endocrinology

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

Journal of Pharmacology and Experimental Therapeutics,
vol. 208, no. 1, pp. 19–23, 1979.
R. C. Rumbaugh and H. D. Colby, “Is growth hormone the
pituitary feminizing factor mediating the actions of estradiol
on hepatic drug and steroid metabolism?,” Endocrinology,
vol. 107, no. 3, pp. 719–724, 1980.
T. Sakuma, Y. Endo, M. Mashino et al., “Regulation of the
expression of two female-predominant CYP3A mRNAs
(CYP3A41 and CYP3A44) in mouse liver by sex and growth
hormones,” Archives of Biochemistry and Biophysics, vol. 404,
no. 2, pp. 234–242, 2002.
Y. Nishida, M. Yoshioka, and J. St-Amand, “Sexually dimorphic gene expression in the hypothalamus, pituitary gland,
and cortex,” Genomics, vol. 85, no. 6, pp. 679–687, 2005.
M. J. Low, V. Otero-Corchon, A. F. Parlow et al., “Somatostatin is required for masculinization of growth hormoneregulated hepatic gene expression but not of somatic growth,”
The Journal of Clinical Investigation, vol. 107, no. 12, pp. 1571–
1580, 2001.
G. C. Desjardins, J. R. Brawer, and A. Beaudet, “Estradiol
is selectively neurotoxic to hypothalamic beta-endorphin
neurons,” Endocrinology, vol. 132, no. 1, pp. 86–93, 1993.
J. R. Brawer, A. Beaudet, G. C. Desjardins, and H. M. Schipper,
“Pathologic eﬀect of estradiol on the hypothalamus,” Biology of
Reproduction, vol. 49, no. 4, pp. 647–652, 1993.
M. J. Kelly and O. K. Ronnekleiv, “Minireview: neural signaling of estradiol in the hypothalamus,” Molecular Endocrinology, vol. 29, no. 5, pp. 645–657, 2015.
E. E. Muller, V. Locatelli, and D. Cocchi, “Neuroendocrine
control of growth hormone secretion,” Physiological Reviews,
vol. 79, no. 2, pp. 511–607, 1999.
L. M. Garcia-Segura, D. Baetens, and F. Naftolin, “Synaptic
remodelling in arcuate nucleus after injection of estradiol
valerate in adult female rats,” Brain Research, vol. 366,
no. 1-2, pp. 131–136, 1986.
K. Shirasu, W. E. Stumpf, and Madhabananda SAR, “Evidence
for direct action of estradiol on growth hormone-releasing
factor (GRF) in rat hypothalamus: localization of (3H)estradiol in GRF neurons,” Endocrinology, vol. 127, no. 1,
pp. 344–349, 1990.
R. M. Señaris, F. Lago, M. D. Lewis, F. Dominguez, M. F.
Scanlon, and C. Dieguez, “Diﬀerential eﬀects of in vivo estrogen administration on hypothalamic growth hormone releasing
hormone and somatostatin gene expression,” Neuroscience
Letters, vol. 141, no. 1, pp. 123–126, 1992.
D. J. Waxman, P. A. Ram, S. H. Park, and H. K. Choi, “Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat
5-related DNA binding protein: proposed role as an intracellular regulator of male-speciﬁc liver gene transcription,” Journal
of Biological Chemistry, vol. 270, no. 22, pp. 13262–13270,
1995.
C. A. Gebert, S. H. Park, and D. J. Waxman, “Regulation of
signal transducer and activator of transcription (STAT) 5b
activation by the temporal pattern of growth hormone stimulation,” Molecular Endocrinology, vol. 11, no. 4, pp. 400–414,
1997.
G. S. Tannenbaum, H. K. Choi, W. Gurd, and D. J. Waxman,
“Temporal relationship between the sexually dimorphic spontaneous GH secretory proﬁles and hepatic STAT5 activity,”
Endocrinology, vol. 142, no. 11, pp. 4599–4606, 2001.

11
[46] G. B. Udy, R. P. Towers, R. G. Snell et al., “Requirement of
STAT5b for sexual dimorphism of body growth rates and liver
gene expression,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 94, no. 14,
pp. 7239–7244, 1997.
[47] D. J. Waxman and M. G. Holloway, “Sex diﬀerences in the
expression of hepatic drug metabolizing enzymes,” Molecular
Pharmacology, vol. 76, no. 2, pp. 215–228, 2009.
[48] M. G. Holloway, Y. Cui, E. V. Laz, A. Hosui, L. Hennighausen,
and D. J. Waxman, “Loss of sexually dimorphic liver gene
expression upon hepatocyte-speciﬁc deletion of Stat5a-Stat5b
locus,” Endocrinology, vol. 148, no. 5, pp. 1977–1986, 2007.
[49] Y. Zhang, E. V. Laz, and D. J. Waxman, “Dynamic, sexdiﬀerential STAT5 and BCL6 binding to sex-biased, growth
hormone-regulated genes in adult mouse liver,” Molecular
and Cellular Biology, vol. 32, no. 4, pp. 880–896, 2012.
[50] R. D. Meyer, E. V. Laz, T. Su, and D. J. Waxman, “Malespeciﬁc hepatic Bcl6: growth hormone-induced block of
transcription elongation in females and binding to target
genes inversely coordinated with STAT5,” Molecular Endocrinology, vol. 23, no. 11, pp. 1914–1926, 2009.
[51] A. Sugathan and D. J. Waxman, “Genome-wide analysis of
chromatin states reveals distinct mechanisms of sexdependent gene regulation in male and female mouse liver,”
Molecular and Cellular Biology, vol. 33, no. 18, pp. 3594–
3610, 2013.
[52] R. I. Nurieva, Y. Chung, G. J. Martinez et al., “BCL6 mediates
the development of T follicular helper cells,” Science, vol. 325,
no. 5943, pp. 1001–1005, 2009.
[53] M. L. Tiell, M. B. Stemerman, and T. H. Spaet, “The inﬂuence
of the pituitary on arterial intimal proliferation in the rat,”
Circulation Research, vol. 42, no. 5, pp. 644–649, 1978.
[54] M. Khorsandi, J. A. Fagin, M. C. Fishbein, J. S. Forrester, and
B. Cercek, “Eﬀects of hypophysectomy on vascular insulinlike growth factor-I gene expression after balloon denudation
in rats,” Atherosclerosis, vol. 93, no. 1-2, pp. 115–122, 1992.
[55] T. Henriques-Coelho, J. Correia-Pinto, R. RonconAlbuquerque Jr. et al., “Endogenous production of ghrelin
and beneﬁcial eﬀects of its exogenous administration in
monocrotaline-induced pulmonary hypertension,” American
Journal of Physiology-Heart and Circulatory Physiology,
vol. 287, no. 6, pp. H2885–H2890, 2004.
[56] Y. P. Xu, J. J. Zhu, F. Cheng et al., “Ghrelin ameliorates
hypoxia-induced pulmonary hypertension via phosphoGSK3β/β-catenin signaling in neonatal rats,” Journal of Molecular Endocrinology, vol. 47, no. 1, pp. 33–43, 2011.
[57] R. Perchard and P. E. Clayton, “Ghrelin and growth,” Endocrine Development, vol. 32, pp. 74–86, 2017.
[58] D. Fedrizzi, T. C. Rodrigues, F. Costenaro, R. Scalco, and M. A.
Czepielewski, “Hypertension-related factors in patients with
active and inactive acromegaly,” Arquivos Brasileiros de Endocrinologia & Metabologia, vol. 55, no. 7, pp. 468–474, 2011.
[59] C. Sardella, D. Cappellani, C. Urbani et al., “Disease activity
and lifestyle inﬂuence comorbidities and cardiovascular events
in patients with acromegaly,” European Journal of Endocrinology, vol. 175, no. 5, pp. 443–453, 2016.
[60] R. Pivonello, R. S. Auriemma, L. F. S. Grasso et al., “Complications of acromegaly: cardiovascular, respiratory and metabolic
comorbidities,” Pituitary, vol. 20, no. 1, pp. 46–62, 2017.
[61] Y. Kurtais, B. S. Tur, A. H. Elhan, M. F. Erdogan, and P. Yalcin,
“Hypothalamic-pituitary-adrenal hormonal responses to

12
exercise stress test in patients with rheumatoid arthritis compared to healthy controls,” The Journal of Rheumatology,
vol. 33, no. 8, pp. 1530–1537, 2006.
[62] T. Zueger, S. Alleman, E. R. Christ, and C. Stettler, “Exerciseinduced GH secretion in the assessment of GH deﬁciency in
adult individuals,” European Journal of Endocrinology,
vol. 165, no. 5, pp. 723–728, 2011.
[63] A. Eliakim, D. Nemet, G. Most, N. Rakover, M. Pantanowitz,
and Y. Meckel, “Eﬀect of gender on the GH-IGF-I response
to anaerobic exercise in young adults,” Journal of Strength
and Conditioning Research, vol. 28, no. 12, pp. 3411–3415,
2014.

International Journal of Endocrinology

MEDIATORS
of

INFLAMMATION

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com
www.hindawi.com

Volume 2018
2013

Gastroenterology
Research and Practice
Hindawi
www.hindawi.com

Volume 2018

Journal of

Hindawi
www.hindawi.com

Diabetes Research
Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2018

International Journal of

Journal of

Endocrinology

Immunology Research
Hindawi
www.hindawi.com

Disease Markers

Hindawi
www.hindawi.com

Volume 2018

Volume 2018

Submit your manuscripts at
www.hindawi.com
BioMed
Research International

PPAR Research
Hindawi
www.hindawi.com

Hindawi
www.hindawi.com

Volume 2018

Volume 2018

Journal of

Obesity

Journal of

Ophthalmology
Hindawi
www.hindawi.com

Volume 2018

Evidence-Based
Complementary and
Alternative Medicine

Stem Cells
International
Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Journal of

Oncology
Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2013

Parkinson’s
Disease

Computational and
Mathematical Methods
in Medicine
Hindawi
www.hindawi.com

Volume 2018

AIDS

Behavioural
Neurology
Hindawi
www.hindawi.com

Research and Treatment
Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Oxidative Medicine and
Cellular Longevity
Hindawi
www.hindawi.com

Volume 2018

